

# Medicare Oncology Medical Home Partnership

*Integrates Cancer Care Advancements to Improve Care Quality and Reduce Costs*

## OVERVIEW

In 2021, Florida Cancer Specialist & Research Institute (FCS) partnered with CVS Health/Aetna to evolve the Oncology Medical Home Program for Medicare patients, which focuses on the patient’s entire cycle of care throughout their cancer journey. The goal was to improve quality and deliver cost-savings using a value-driven framework with an opportunity for shared savings. While FCS already had an established strategic focus on value-based programs, consistently receiving exceptional scores in partnerships with Accountable Care Organizations, Managed Service Organizations and other commercial/Medicare Advantage payers across Florida aimed at reducing care costs and prioritizing patient outcomes and satisfaction, this evolution sought to specifically integrate advanced molecular genetic testing and clinical trial research capabilities into the program.

**By initiating a collaboration with FCS, CVS Health/Aetna was able to enhance its Medical Oncology Medical Home Program to encompass the pioneering use of Next-Generation Sequencing and clinical trial research.**



## APPROACH

### Cancers Included in Attribution Model

- |                              |                      |
|------------------------------|----------------------|
| bladder cancer               | gynecological cancer |
| breast cancer                | head and neck cancer |
| chronic lymphocytic leukemia | hepatobiliary cancer |
| chronic myeloid leukemia     | kidney cancer        |
| colon cancer                 | lung cancer          |
| esophageal cancer            | lymphoma             |
| esophagogastric cancer       | multiple myeloma     |
| gastric cancer               | pancreatic cancer    |
|                              | prostate cancer      |
|                              | rectal cancer        |


**CVS Health/Aetna worked closely with FCS to define an appropriate attribution model, identifying patients receiving care for specific cancer diagnoses.**

The providers would share accountability in quality measurements resulting from the pioneering use of Next-Generation Sequencing (NGS) testing in treatment planning as well as outcomes for patients accepted and enrolled into clinical trials. A reduction in hospitalizations in alignment with NCCN Guidelines® and the use of biosimilar drugs were key outcome metrics for achieving shared savings.

## RESULTS

In the first year of the program, January 2021 – January 2022, FCS achieved shared savings when compared against a control group, demonstrating the statewide practice's constant ability to provide care at a lower cost while providing high quality care to patients. Following a mid-year evaluation of the program results by FCS and CVS Health/Aetna, NGS testing parameters were modified, and the patient population was expanded. During this subsequent period, inpatient hospital stays dropped 13.8%, emergency room visits were 31.5% lower and cancer related drug costs were down 7.7%.

### Study Group Compared to FCS PMPM



**FCS % difference lower from the control group**



## CONCLUSION

Following a collaborative first year, resulting in adjustments to budget methodology, utilization metrics and quality measures, the partners were able to evaluate the impact of these value-based initiatives and refine targets for subsequent years of the program. The partners are looking to explore the evolution of the program through a continual focus on ensuring the availability of high-quality, cost-effective care, leading to favorable outcomes for patients throughout their cancer journey. Their efforts will serve as a model partnership and help to further define value-based care.